Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]
Sagel SD +15 more
europepmc +1 more source
The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review. [PDF]
Girouard H +5 more
europepmc +1 more source
12-month outcomes of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in rare CFTR missense variant. [PDF]
Vekaria S, Al-Abbasi H, Mulrennan S.
europepmc +1 more source
Editorial: Real-world experience with CFTR modulator therapy
Burkhard Tümmler +3 more
doaj +1 more source
Elexacaftor-Tezacaftor-Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis. [PDF]
Lin A +6 more
europepmc +1 more source
Comparison of Stool Microbiome in Children with Cystic Fibrosis Treated with and Without Elexacaftor-Tezacaftor-Ivacaftor-A Pilot Study. [PDF]
Sankararaman S +9 more
europepmc +1 more source
Off-label treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: real-world evidence from the German CF Registry. [PDF]
Stahl M +5 more
europepmc +1 more source
Prenatal Elexacaftor/Tezacaftor/Ivacaftor for Fetal Meconium Ileus: First Italian Case and Narrative Overview of the Emerging Evidence. [PDF]
Boni A +11 more
europepmc +1 more source
Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start. [PDF]
Selvadurai H.
europepmc +1 more source
Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. [PDF]
Blankenship S +6 more
europepmc +1 more source

